戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 115 patients enrolled, 111 were treated with pralatrexate.
2 alized papular rash, he received one dose of pralatrexate.
3                   Patients were treated with pralatrexate (10 to 25 mg/m(2)) and romidepsin (12 to 14
4                                              Pralatrexate 15 mg/m(2)/wk for 3/4 weeks shows high acti
5  The recommended phase 2 dose was defined as pralatrexate 25 mg/m(2) and romidepsin 12 mg/m(2) every
6 y evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity
7 r selected market available drug candidates, Pralatrexate and Azithromycin were confirmed to effectiv
8 th delayed confirmatory trials: lessons from pralatrexate and belinostat for T-cell lymphoma.
9      We also identified disease responses to pralatrexate and enasidenib in some patients.
10                          Coadministration of pralatrexate and romidepsin was safe, well tolerated, wi
11 linic, such as pemetrexed, methotrexate, and pralatrexate, are transported into tumor cells primarily
12 ell lymphomas and TCL have demonstrated that pralatrexate demonstrates activity superior to tradition
13 e-escalation strategy identified recommended pralatrexate dosing for patients with CTCL that demonstr
14                         The high affinity of pralatrexate for RFC-1 significantly improves its intern
15  and clinical studies have demonstrated that pralatrexate has significant activity against TCL.
16                                              Pralatrexate has significant single-agent activity in pa
17               We investigated the effects of pralatrexate in a patient with adult T-cell lymphoma/leu
18                    To our knowledge, PROPEL (Pralatrexate in Patients with Relapsed or Refractory Per
19                                              Pralatrexate induced durable responses in relapsed or re
20        Here we present in vivo evidence that pralatrexate-induced erosions in skin affected by adult
21                                              Pralatrexate-induced skin erosions may indicate response
22                                              Pralatrexate is a novel antifolate designed to have high
23                                              Pralatrexate is a novel antifolate with high affinity fo
24                                              Pralatrexate is a novel antifolate, which shows increase
25 or the first time, our study discovered that Pralatrexate is able to potently inhibit SARS-CoV-2 repl
26                                              Pralatrexate is an antifolate designed to be internalize
27 is and are not the result of cytotoxicity by pralatrexate on keratinocytes.
28  single institution dose-escalation study of pralatrexate plus romidepsin designed to determine the d
29 els of PTCL, we initiated a phase 1 study of pralatrexate plus romidepsin in patients with relapsed/r
30                         The phase 1 study of pralatrexate plus romidepsin resulted in a high response
31 en, obatoclax, and gossypol), antifols (e.g. pralatrexate), proteasome inhibitors (e.g. bortezomib),
32 ion, have been investigated in this context: pralatrexate, romidepsin, belinostat, and brentuximab ve
33  US Food and Drug Administration approval of pralatrexate, the first drug approved for this disease.
34  influence the clinical decision to continue pralatrexate treatment.
35                                              Pralatrexate was administered for a median of 4 cycles;
36                               Romidepsin and pralatrexate were approved by the US Food and Drug Admin